Search References Drug Actions/Targets About Access data Feedback
Sign In
mitontu@gmail.com
2021 MitoTox | (CC BY-NC 4.0)
Drug

D0014 | Bleomycin

Molecular Formula C55H84N17O21S3+
Molecular Weight 1415.6
Structure
State solid
Route of elimination It was reported that patients with moderately severe renal failure excreted less than 20% of the dose in the urine.
Protein binding 0.01
Half life 115 minutes
Absorption Systemic absorption is approximately 45%.
Trade names Blenoxane
Description glycopeptide antibiotics; antineoplastic; inhibits DNA metabolism

L

L01DC01 Bleomycin


[L01DC] Other cytotoxic antibiotics


[L01D] CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES


[L01] ANTINEOPLASTIC AGENTS


[L] Antineoplastic and immunomodulating agents

Organism Test type Route Dose (normalized dose) Effect Source
mouse LD50 intraperitoneal 35mg/kg (35mg/kg) Journal of Antibiotics. Vol. 37, Pg. 239, 1984.
rat LD50 intraperitoneal 168mg/kg (168mg/kg) "Bleomycin: Current Status and New Development, Papers Presented in a Symposium, Oakland, CA, 1977," Carter, S.K., et al., eds., New York, Academic Press, Inc., 1978Vol. -, Pg. 311, 1978.
human LDLo intravenous 351mg/kg (351mg/kg) American Journal of Clinical Pathology. Vol. 58, Pg. 501, 1972.
mouse LD50 intravenous 53mg/kg (53mg/kg) Journal of Antibiotics. Vol. 31, Pg. 667, 1978.
human LDLo intramuscular 418mg/kg (418mg/kg) American Journal of Clinical Pathology. Vol. 58, Pg. 501, 1972.
mouse LD50 intraperitoneal 35mg/kg (35mg/kg) Antibiotics Annual. Vol. 2, Pg. 806, 1954/1955.
mouse LD50 oral > 2gm/kg (2000mg/kg) Japanese Journal of Antibiotics. Vol. 28, Pg. 1, 1975.
mouse LD50 subcutaneous 188mg/kg (188mg/kg) Yakkyoku. Pharmacy. Vol. 25, Pg. 573, 1974.
rat LD50 subcutaneous 168mg/kg (168mg/kg) Yakkyoku. Pharmacy. Vol. 25, Pg. 573, 1974.
mouse LD50 intramuscular 270mg/kg (270mg/kg) Pharmaceutical Chemistry Journal Vol. 17, Pg. 785, 1983.
dog LD oral > 100mg/kg (100mg/kg) Japanese Journal of Antibiotics. Vol. 28, Pg. 1, 1975.
mouse LDLo intratracheal 14mg/kg (14mg/kg) Toxicology Letters. Vol. 30, Pg. 63, 1986.
rat LD oral > 200mg/kg (200mg/kg) Japanese Journal of Antibiotics. Vol. 28, Pg. 1, 1975.
rat LDLo intratracheal 4units/kg (4units/kg) Lung. Vol. 161, Pg. 287, 1983.

  • Choriocarcinoma

  • Dysplasia

  • Hodgkin's disease

  • Hodgkin's disease lymphocyte depletion type stage unspecified

  • Hodgkin's disease lymphocyte predominance type stage unspecified

  • Lymphoma

  • Malignant pleural effusion

  • Neoplasm

  • Neoplasm malignant

  • Pleural effusion

  • Pulmonary toxicity

  • Renal impairment

  • Squamous cell carcinoma

  • Testis cancer

  • Body temperature increased (0.005)

  • Mucosal inflammation (0.003)

  • Pneumonia (0.001)

  • Pulmonary fibrosis (1e-04)

  • Stomatitis (0.003)

    • 11056-06-7 BLM Bleocin
    Bleomicin Bleomicina Bleomicina [INN-Spanish]
    Bleomycin A(2) Bleomycin B(2) Bleomycin [INN:BAN]
    Bleomycin [INN] Bleomycin sulfate Bleomycine
    Bleomycine [INN-French] Bleomycins Bleomycinum
    Bleomycinum [INN-Latin] C55H85N17O21S3 CCRIS 2754
    DB00290 HSDB 3208 LMPK14000006
    LS-524 NDC 0015-3010 NSC 125066
    SCHEMBL21090952 bleomycin bleomycin a2

    DrugBank Name Bleomycin
    DrugBank DB00290
    CAS Number 11056-06-7, 1400-95-9
    PubChem Compound 5360373
    KEGG Compound ID C06854
    KEGG Drug D07535
    PubChem.Substance 46509116
    ChEBI 22907
    PharmGKB PA448645
    ChemSpider 4514492
    BindingDB 50122169.0
    TTD DAP000531
    Wikipedia Bleomycin
    HET BLM
    DPD 11448|8453

    1. Brar et al., 2012